Company intelligence / Profile preview

Crucell

Leiden, Netherlandsjnj.com ↗

Ownership: Private
Employees: ~1300
Development stage: Commercial

Overview

Crucell was a leading independent vaccine manufacturer with several commercial products—most notably Quinvaxem®, a pentavalent pediatric vaccine distributed globally. The company had a strong pipeline in both clinical and preclinical stages focused on infectious diseases. Its proprietary PER.C6® technology was widely licensed to major pharma companies for biologics production. At the time of its acquisition by Johnson & Johnson in 2011 for approximately $2.4 billion, Crucell had sold over 180 million doses of Quinvaxem since launch in 2006

Therapeutic areas: Infectious Diseases
Modalities: Vaccinesmonoclonal antibodies (mAbs)recombinant proteins
Industry: Biotech

Drug pipeline

3 assets

Quinvaxem

Commercial

Indications: Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae type b

2 more assets in the full pipeline.

Request access →

Partnerships

DSM BiologicsSanofi-AventisNovartisPfizer/WyethGSKCSL LimitedMerck & Co.Johnson & Johnson was initially a strategic partner before full acquisition.

Beyond the preview

Go deeper on Crucell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crucell.

Explore the full profile